文献速递白血病

伊马替尼治疗后尼洛替尼两种巩固周期后的无治疗缓解:III期ENESTPath研究结果

Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.
PubMed 文献 · Leukemia · 2026-01-19

ENESTPath研究纳入620例伊马替尼治疗超过2年未达深度分子学缓解的慢性期Ph+/BCR::ABL1+ CML患者,换用尼洛替尼300mg每日两次。治疗24个月后达稳定DMR者随机进入TFR(Arm 1)或继续巩固12个月后再TFR(Arm 2)。12个月TFR成功率Arm 1为31.9%、Arm 2为37.5%(p=0.383),24个月分别为29.4%和30.8%,2年与3年尼洛替尼巩固无差异。

要点

  • 伊马替尼未达稳定DMR者换用尼洛替尼300mg BID可提供TFR机会。
  • 尼洛替尼巩固2年与3年的12个月TFR成功率无显著差异。
  • 12个月TFR成功率Arm 1 31.9%、Arm 2 37.5%(p=0.383)。

核心结论

  • 伊马替尼一线治疗未达稳定DMR的CML患者换用尼洛替尼300mg BID后,尼洛替尼巩固2年与3年的TFR成功率无差异。

研究设计与样本

  • III期ENESTPath研究,纳入620例伊马替尼治疗>2年未达DMR的慢性期Ph+/BCR::ABL1+ CML患者,换用尼洛替尼300mg BID。
  • 治疗24个月后达稳定DMR者随机分为TFR组(Arm 1,n=120)和继续巩固12个月后再TFR组(Arm 2,n=119)。

主要发现

  • 620例中239例(38.5%)达稳定MR4.0并随机分组。
  • TFR阶段12个月MR4.0率:Arm 1为31.9%,Arm 2为37.5%(p=0.383)。
  • TFR阶段24个月MR4.0率:Arm 1为29.4%,Arm 2为30.8%。

关键数值与推荐

  • 主要终点为TFR阶段12个月时无分子学复发且维持TFR(≥MR4.0,BCR::ABL1IS≤0.01%)的患者比例。

临床怎么用

  • 伊马替尼一线治疗未达稳定DMR的CML患者可考虑换用尼洛替尼300mg BID以争取TFR。
  • 尼洛替尼巩固2年即可考虑TFR,延长至3年未显示额外获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase 3 ENESTPath study investigated treatment-free remission (TFR) rates in patients with chronic Philadelphia chromosome-positive (Ph+) and/or BCR::ABL1+ chronic myeloid leukemia who had not achieved deep molecular response (DMR) after >2 years of imatinib treatment and were switched to nilotinib 300 mg twice daily (BID). After 24 months of treatment, patients with a stable DMR were randomized to either enter the TFR phase (Arm 1) or continue nilotinib consolidation for an additional 12 months and then enter the TFR phase if in stable DMR (Arm 2). The primary endpoint was the proportion of patients who remained in TFR (≥MR4.0 [BCR::ABL1IS ≤ 0.01%]) without molecular relapse at the end of 12 months. Of the 620 patients enrolled, 239 (38.5%) achieved stable MR4.0 and were randomized to Arm 1 (n = 120) or Arm 2 (n = 119). In the TFR phase, MR4.0 rates at 12 months (Arm 1: 31.9%, Arm 2: 37.5%; p = 0.383) and 24 months (Arm 1: 29.4%, Arm 2: 30.8%) revealed no differences in TFR success between 2 and 3 years of nilotinib. Irrespective of the consolidation duration, switching to nilotinib 300 mg BID provided the opportunity to achieve TFR if patients were unable to reach stable DMR with first-line imatinib.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Rea D, Kyrcz-Krzemien S, Sportoletti P, et al. Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results. Leukemia. 2026. PMID: 41555010. doi:10.1038/s41375-025-02847-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。